Entera Bio Ltd.: Spruce Street Capital LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Spruce Street Capital LP disclosed a stake of more than 5% in Entera Bio Ltd. via a Schedule 13G filing with the SEC (accession 0000902664-26-004526). The exact share count and percentage were not specified in the filing headline. The disclosure signals a new or increased position by the investor in the clinical-stage biotech. Investors will watch for further detail on the size and intent of the holding, and for any subsequent 13G amendments.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Entera Bio Ltd., Spruce Street Capital LP